Real-World Outcomes With Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
ESMO Open 2024 Jun 03;9(6)103464, AR Filippi, J Bar, C Chouaid, DC Christoph, JK Field, R Fietkau, MC Garassino, P Garrido, VD Haakensen, S Kao, B Markman, F McDonald, F Mornex, M Moskovitz, S Peters, A Sibille, S Siva, M van den Heuvel, P Vercauter, S Anand, P Chander, M Licour, AR de Lima, Y Qiao, N GirardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.